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ABSTRACT
C-C motif Chemokine Ligand 3 Like 1 (CCL3L1) is characterized as a gene with copy number variable (CNV) and 
clustered at the segmental duplication on chromosome 17q12. CCL3L1 is responsible for the production of mac-
rophage inflammatory protein (MIP) 1α that plays an important function in the immune system and host defense. 
Various copies range of CCL3L1 have been reported and associated with the diseases in different populations. Thus, 
this review aimed to summarise the distribution of CCL3L1 copy number from different populations according to the 
geographical region and highlighted the lacking of data from Malaysian population, which is one of the multi-ethnic 
countries due to the impacts of CCL3L1 copies on various diseases. Besides, we also outlined the methodologies 
available for the copy number typing. In overall, this review could provide significant information on the role of 
CCL3L1 copies in disease association and as well as providing evidence on the population diversity.
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Genome is a complete set of DNA which responsible 
for all the instructions and information within a living 
organism (1). The differences of DNA between individuals 
are termed as the genomic variation (2). Genomic 
variation includes single nucleotide polymorphism 
(SNP) known as the most common genetic variation 
and copy number variation (CNV) formally known 
as gene duplication (3). Generally, CNV refers to an 
alteration of genetic sequence including deletion and 
duplication of DNA segments larger than 1 kb. Genes 
with CNV includes among others beta-defensin (DEFB), 
alpha-synuclein (SNCA), Fc fragment of IgG receptor III 
(FCGR3) and salivary amylase gene (AMY1) (4). 
CCL3L1 is gene with CNV located on the chromosome 
17q12 and encodes for macrophage inflammatory 
protein (MIP) 1α, a chemokine that involves in a variety 
of immune cells and plays a part in anti-tumour immunity 
(5). Different range of CCL3L1 copy numbers has been 
observed and seem to be unique to the population and 
geographical region. Online searches through journal 
websites, research articles, and database (PubMed, 
ScienceDirect, SAGE and Database of Genomic Variants 
websites), shows no reports on the Malaysian population 
or in disease association studies with CCL3L1. Thus, 
more studies are encouraged to be conducted in order 
to discover the copy number range in Malaysia so that 
this information could contribute in minimising the gap 
in the attempt of mapping the genomic CNVs. 
COPY NUMBER VARIATION (CNV)
CNV is defined as gaining or losing of DNA segments 
when it is compared with the reference genome. Gene 
dosage imbalance can be considered as the most 
outcome of CNV by changing the DNA sequences (6). 
Until November 2018, there are 72 entries of research 
related to CNV displayed in the online database on the 
website of Database of Genomic Variants (http://dgv.
tcag.ca/dgv/app/home) which represents the growing 
study of CNVs in current research field. 
COPY NUMBER VARIABLE OF CCL3L1
Distribution of CCL3L1 Copy Number (CN) among 
Populations
Many studies on CCL3L1 copy number were carried 
out in several populations, however the number of 
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investigation among the Asian populations is still 
minimum. As shown in Fig. 1, a number of CCL3L1 studies 
have been carried out in different countries; United 
Kingdom (7,8), Norway (9), Estonia (10), Germany (11), 
French (12), Tunisia (12), Tanzania (13), Ethiopia (13), 
Zimbabwe (14), Peru (15), Botswana (15), South African 
(15), China (16), Korea (17), Japan (18), and Ohio, 
Columbia and San Antonio (19). The pattern of CCL3L1 
copy number range could be further analysed based on 
the geographical regions. CN between zero and seven 
was reported in the European regions which include 
United Kingdom, Norway, Estonia, France and Tunisia 
while Germany records up to 12 copies. Meanwhile, 
in the African regions comprising Ethiopia, Tanzania, 
Zimbabwe, South Africa and Botswana, CCL3L1 copy 
number ranged from 0 to 14. Studies in the Asian region 
that includes the Indian, Korean, Chinese and Japanese 
populations reported copy number ranged between 0 
and 10.
CCL3L1 copy number has been proven to be varied 
in different populations but such information is yet 
to be reported in Malaysia. From Fig. 1, it could be 
proposed that the copy number range of CCL3L1 
among Malaysian population of different origins might 
be from 0 to 10 copies based on the geographical 
factors of Malaysia which is a part of the Asian region. 
However, this is only an assumption and requires 
valid genetic and scientific evidences. Indeed, more 
investigations on genetic diversity among Malaysians 
should be performed to delineate our ancestral history. 
Thus, documentation on the CCL3L1 copy number 
among Malaysians will provide valuable fundamental 
information in the genetic database. Therefore, future 
investigation on the association of gene copy number 
towards the susceptibility of gene-related diseases 
could be determined when compared to the reference 
distribution. 
A recent study discovered that various frequencies of 
CCL3L1 were observed among four native Peninsular 
Malaysians; Malay, Negrito, Senoi and Proto-Malay, 
with a higher frequency of duplication in Negrito as 
compared to the other groups (20). However, the exact 
number of CCL3L1 copies has not been fully determined 
in this report. This is mainly due to SNP array that was 
performed in this study is inadequate to determine the 
exact copy number of multi-allelic CNVs. Uniquely, 
Malaysia is a multi-ethnic country which comprises 
a majority of the Malay, Chinese and Indian ethnics, 
therefore it is necessary to investigate the possibility of 
significant differences between ethnic groups. In fact, 
the findings will aid in further understanding of human 
genetic variation in a similar population with the multi-
ethnic background.
Numerous of studies were performed on the association 
of CCL3L1 with disease susceptibilities (Table I). Table I 
summarized the studies of CCL3L1 copy number among 
the diverse population (control group) from the year 2010 
until 2016. The range of CCL3L1 copy numbers varies 
from one population to another. Discrepancies showed 
in the disease association of CCL3L1 copy number 
suggested further investigations need to be carried out. 
Different techniques and methodologies were used in 
the quantification of CCL3L1 copy numbers whereby 
qPCR was the most preferred method (11). However, the 
qPCR method showed declining usage since the year 
2011 as other methods such as PRT gives high accuracy 
and efficiency in the quantification of  CCL3L1 copy 
number (7). 
Functional Impacts of CCL3L1 Copy Number Variable 
Gene
CCL3L1 was previously known as LD78β and paralogue 
to CCL3 (invariant copy number) (21). The term 
paralogue is defined as homologues derives from the 
same ancestral gene with similar sequence but reside at 
different locations within the same genome and have a 
slightly different function (22). Both CCL3 and CCL3L1 
are 96% identical in nucleotides and proteins (23). 
Two isoforms of MIP-1α; LD78α and LD78β which are 
encoded by these highly related non-allelic genes CCL3 
and CCL3L1, respectively (24). MIP-1α is classified under 
the MIP-1 family which is involved in inflammatory 
ailments such as asthma, wound healing, and arthritis 
(25). Thus, it plays a crucial role in pathogen response 
and cell damages. MIP-1α protein is also a critical 
macrophage chemoattractant vital in the repair process 
of  cutaneous wound that helps the healing process (26).
LD78β is two-fold more efficient at chemo-attracting 
human lymphocytes than the LD78α isoform (27). 
However both LD78α and LD78β products were able 
to bind to specific chemokine receptors such as CC 
motif chemokine receptor (CCR) 1, 3 and 5 to activate 
their functional effects (28). Each binding will mediate 
a different function. Conversely, LD78β produced 
by CCL3L1 was found to be in a truncated-2 form 
which leads to the higher binding affinity to CCR5 by 
approximately 6-folds (29). 
Molecularly, CCL3L1 is located at base pairs 250,577 
Figure 1: Distribution of CCL3L1 copy number in differ-
ent populations.
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Association of CCL3L1 copy 
number with diseases





Europe (Estonian) 0 to 6 copies qPCR HIV-1 
Fewer copies than two associated 
with risk of HIV seropositive
374 samples 2010
Europe (Germans) 0 to 12 copies qPCR Hepatitis C
Two or fewer copies associated 
with the risk of Hepatitis C
254 cases, 210 
controls
2010
Asia (Japanese) 1 to 9 copies qPCR Kawasaki disease
Higher than four copies 
associated with increased risk of 
Kawasaki disease





0 to 7 copies qPCR Tuberculosis
Higher copy number of two 
associated with risk of active 
tuberculosis
114 cases, 184 
controls
2011
Europe (British) 0 to 4 copies PRT
Rheumatoid arthritis, 
Psoriasis and Chron’s 
disease
No association 1581 samples 2011
Asia (Korean) 1 to 5 copies qPCR Asthma
Low copy number associated 
with risk of asthma
161 cases, 372 
controls
2011
Asia (Korean) 1 to 5 copies qPCR Kawasaki disease No association 
459 cases, 496 
controls
2012
Africa (Tanzanian) 1 to 10 copies PRT Malaria
Weak evidence of low copy 





0 to 5 copies PRT Rheumatoid arthritis No association






0 to 8 copies 
(Ethiopian) 0 




and  immune 
reconstitution
No association towards viral 
load, however, low copy number 





0 to 6 copies PRT Tuberculosis No association





0 to 10 copies PRT Tuberculosis No association





0 to 12 copies PRT Tuberculosis No association 56 cases, 165 controls 2014
Europe (Tunisian) 0 to 7 copies ddPCR Rheumatoid arthritis
Higher than two copy number 
associated with rheumatoid 
arthritis risk
166 cases, 102 
controls
2016
Europe (French) 0 to 4 copies ddPCR Rheumatoid arthritis
Higher than two copy number 
associated with rheumatoid 
arthritis risk
100 trio families (one 
patient with two 
unaffected parents)
2016
to 252,466 on chromosome 17q21.1 (Homo sapiens 
Annotation Release 108, GRCh38.p7) (30). This gene 
lies within the copy variable repeat unit (approximately 
90 kb in size) together with CCL4L1, TBC1D3, and 
LTR61 on chromosome 17. Both CCL3L1 and CCL4L1 
are neighbouring their paralogues, CCL3 and CCL4, 
respectively (7). The position of CCL3L1 and CCL4L1 
on the chromosome with their paralogues is illustrated 
in Fig. 2.
Variable copies of CCL3L1 may affect the susceptibility 
of individuals towards immune disease since the 
protein encoded by this gene, participates in the 
immunoregulatory and inflammatory process (31). 
Gonzalez et al. (2005) have demonstrated that low 
CCL3L1 copy number may increase the risk of the 
HIV-1 susceptibility among African populations (32). 
Different study suggested that an individual is positively 
susceptible to HIV-1 infection in the case of CN loss 
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(<2) in CCL3L1 (10). Nevertheless, high copy number 
of CCL3L1 may produce abundant chemokine and 
suppress the infection activity of HIV-1 as it acts as the 
competitive inhibitor of the HIV-1 virus (33). 
Additionally, Lee and friends have shown the association 
of one copy or less of CCL3L1 in promoting asthma 
attack among Korean populations (34). Protein produced 
by CCL3L1 was found to hinder the allergic response of 
asthma in a dosage depending on the expression level 
of IL-10. IL-10 acts as an anti-inflammatory cytokine and 
reduces the level of protein, which may trigger positive 
responses to the asthma attack. Therefore, a low copy 
number of CCL3L1  may increase the risk of asthma in 
an individual (34). 
Nevertheless, Kawasaki disease is linked to the high 
copy number of CCL3L1. Kawasaki disease is an 
inflammatory disorder involving systemic vasculitis 
and it is common among young children (35). A study 
in Japan reported that the risk of Kawasaki disease is 
correlated higher than four copies of CCL3L1 due to 
the elevated inflammatory chemokine production by a 
high amount of CCL3L1 copy number, which eventually 
triggers the antigenic stimulus. Consequently, high 
CCL3L1 copy number may increase the susceptibility of 
developing the disease (35). However, another finding 
in Korea failed to replicate the results due to the different 
methodology used in the study (17). 
Meanwhile among the Colombians, individuals with 
more than two copies of CCL3L1 have an increased 
risk of tuberculosis activation. A higher copy number 
of CCL3L1 will increase the chemokine production 
that might alter the immune response, resulting the 
increase activation of tuberculosis (36). Conversely, 
studies in Tunisia and France showed that more than 
two copies of CCL3L1 resulted in significantly higher 
risk of rheumatoid arthritis (12). When the CCL3L1 
copy number is greater than two, it will increase the 
chemokines level and irritate the synovium. This irritated 
synovium may trigger a massive response by leukocytes 
and chemotactic activity which eventually contribute 
to rheumatoid arthritis (37). Measuring of  CCL3L1 
copy number range towards an association with certain 
disease requires careful strategy particularly on the 
methodology approaches and data analysis. 
MOLECULAR TECHNIQUES FOR COPY NUMBER 
TYPING
Discrepancy in reporting the copy number might result 
from different technologies applied in the studies. A 
reproducible, reliable and high throughput methods is 
important in quantification of CNV genes. Thus, several 
technologies for measuring the CNV genes with their 
own strengths and limitation has been described here.
Southern Blotting
Southern blotting was named after Sir Edwin Southern, 
a British biologist who developed this method (38). The 
procedure of Southern blotting is crucial during the 
DNA fragmentation as it involves the use of restriction 
endonuclease enzyme. Gel electrophoresis is then 
performed to transfer DNA fragments to a nylon or 
nitrocellulose membrane through the blotting process. 
For the identification, the labelled probe is hybridized 
to the target site of DNA fragments and the results are 
then analysed with an autoradiograph (39). Intensities 
obtained between the bands are compared to a reference 
band. High or low intensities ratio indicate the increase 
or decrease of CNV respectively (40).
There were few studies that applied the Southern blotting 
analysis and densitometry to quantify the copy number. 
The radiolabelled probe was specific for CCL3L1 cDNA 
to allow hybridization by autoradiographs. The cDNA 
probe was used in this analysis to ensure the exact 
breakpoint (41). The analysis of the copy number will 
show two bands of EcoRI with its own molecular size 
whereby 4.2 kb reflects CCL3 and 4.8 kb for CCL3L1. 
The ratio is calculated based on the intensities between 
these two bands and considered as the copy number of 
CCL3L1 (37). Unfortunately, Southern blot showed less 
accuracy in obtaining copy number when compared 
to the qPCR as the analysis of Southern blot strongly 
relies on the exposure time, transferring of DNA, and 
efficiency of hybridization. These factors may lead to 
inconsistency of the result produced by Southern blot 
analysis and densitometry. Besides, the huge amount of 
genomic DNA required to perform a good result makes 
it less desirable for researchers to use this technique (37).
Fluorescence in situ Hybridization (FISH)
FISH is one of the methods used to quantify CNV which 
was developed in the late 1980s for human genes 
mapping (42). Other variants of FISH were developed 
such as fibre-FISH, spectral karyotyping (SKY) and 
Multicolour-FISH (M-FISH). Conventional FISH either 
on metaphase or interphase chromosomes may identify 
duplication (large >10Mb and small of 40kb) and 
deletion (more than 40kb) and have been performed as 
a validation tool (43). 
Fiber-FISH was used as a validation tool for quantifying 
Figure 2: Three systems of PRT in CCL3L1 copy number quan-
tification; CCL3A amplifies CCL3 and CCL3L1, CCL4A am-
plifies CCL4 and CCL4L1 and LTR61A amplifies LTR61 and 
unlinked reference on chromosome 10. 
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emitted from the probe of CCL3L1 and the reference 
gene, β globin. Later, the value of Ct is identified and 
determined as the initial target amplification. The Ct 
value is then converted into a standard curve to calculate 
the ratio of CCL3L1 to the β globin and is multiplied by 
two. The final copy number is determined by rounding 
off the value to the nearest copy number integer (40). 
However, some qPCR findings on CCL3L1 copy number 
were not consistent due to shift of the results to the right 
when compared to the Paralogue Ratio Test caused by 
the amplification of CCL3L1 pseudogene. This indicates 
the probability in the false-positive calling of CCL3L1 
copy number (52). In addition, the chemistry of qPCR 
amplification limits the ability to genotype multi-allelic 
CNV as it gives relatively broader distributions. It is also 
challenging to design a primer of small size CNV or CNV 
within a repetitive region and with the necessity to run 
each sample in triplicate leading to a higher cost (52).
Multiplex Ligation-dependent Probe Amplification 
(MLPA)
MLPA is a PCR-based method which offers simultaneous 
detection of duplication and deletions up to 40 target 
sequences (53) where  the amplification takes place 
on the MLPA probes instead of DNA samples (54). 
This method was used in screening a large number of 
genes with the alteration in the copy number and could 
potentially becomes a gold standard in the molecular 
diagnosis of genetic-related diseases due to the deletion 
or duplication (55). Determination of CCL3L1 copy 
number by MLPA was successfully performed previously 
by combining two sets of probes (two colours). Different 
fluorophore was labelled for each probe, targeting 
the CCL3L1 at exon 1 and exon 3 (56). Two probes 
with known copy number (diploid) were used in the 
normalization process as reference probes. The targeted 
genes for the reference probes were EP300 and CREBBP 
located on chromosome 22 and 16 respectively. The 
MLPA probes of CCL3L1 and two additional reference 
loci were firmly held by hybridization and ligation 
on the target sequence of DNA (56). Relative peak 
heights were extracted and the ratios were generated to 
determine the losses or gains of the target DNA sequence 
(56). However, it is suggested to perform independent 
multiple measurements for copy number quantification 
to accurately distinguish the copy number assigned to 
the respective samples (56).
Paralogue Ratio Test (PRT)
PRT is a multiplex PCR-based technology where 
the primers are specifically designed to amplify 
one from the repeat unit (test) and another from the 
constant unit (reference) loci simultaneously. PRT 
has been considered as a much simplified and robust 
methodology with a high throughput and accurate in 
measuring the copy number of CNV with minimum of 
10ng DNA only (57). Two duplex PCRs were used in 
quantifying the CCL3L1 copy number. The first PCR 
had combined two systems; CCL3A and LTR61A while 
copy number of CCL3L1 among the Yoruba from 
Ibadan (YRI), Nigeria population (13). Stretched DNA 
from lymphoblastoid cell lines is prepared on the 
slides. Labelled fosmid probes used in this method are 
G248P85689G4 (white), G248P84883A8 (green) and 
G248P8961D8 (red) to determine the absolute copy 
number of CCL3L1. Once the detection succeeds, the 
slides are mounted with mounting solution containing 
4’,6-diamidino-2-phenylindole and fluorescent 
microscope is used to visualize their chromosomal 
target site. These probes emit light when viewed under 
a fluorescent microscope which displays CCL3 in green, 
CCL3L1 in red, and a DNA segment between these two 
genes in white (13). Indeed, the FISH-based technique 
was primarily chosen due to its high resolution, accuracy 
and precision in abnormality detection. However, 
this technique requires labour-intensive workflow 
and a high-quality sample. Moreover, the presence of 
overlapping signals in highly variable regions makes it 
challenging to interpret the results (40).
Complex Genomic Hybridization (CGH)
CGH is developed to map DNA sequence copy number 
within the genome in molecular cytogenetic analysis. 
This technique simultaneously compares two genomic 
DNA samples labelled with different fluorescent dye. 
The mixture of tumour labelled with green and normal 
DNA with red fluorochrome in a 1:1 ratio is hybridised 
to normal human metaphase spread of chromosomes. 
It is a fast screening process with no cell culture 
requirement which offers researchers to analyse the 
chromosomal changes in solid tumours (44). Later, array 
CGH (aCGH) was introduced to overcome the limitation 
of low resolution by conventional CGH. In aCGH, small 
DNA segments were used as a target instead of targeting 
metaphase of reference chromosomes (45). Human 
Whole-Genome TilePath (WGTP) array is an aCGH 
platform where the ratio of green-to-red fluorescence 
for each DNA segment arrayed on the microscope slide 
is determine as the distinction between losses, gains or 
balanced status. (46). This method is used in the detection 
of CNV and presented as an additional diagnostic tool. 
However, there are limitations especially when it comes 
to detecting a balance alteration of DNA sequence such 
as translocation and inversion (47).
Quantitative Polymerase Chain Reaction (qPCR)
Polymerase chain reaction (PCR) was firstly discovered 
by Kary Mullis (1984) (48) and real-time PCR, also 
known as qPCR was then developed. It is able to 
measure the accumulation of PCR products by dual-
labelled fluorogenic probes (49). qPCR comes with some 
advantages, such as lesser chance of contamination in 
the laboratory since it is performed in a closed system 
(50). Besides, qPCR gives a high yield of samples 
throughout due to the absence of post-PCR process (51). 
This method has been extensively used in quantifying 
the copy number loss or gain of CCL3L1. During the 
amplification process, qPCR detects fluorescence 
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second PCR combined CCL4A and LTR61A. CCL3A 
is used to amplify both CCL3L1 (test locus) and CCL3 
(reference locus) while, CCL4A amplifies CCL4L1 (test 
locus) and CCL4 (reference locus). LTR61A serves as an 
additional system that measures the long terminal repeat 
(LTR) in between CCL3L1 and CCL4L1 against unlinked 
reference locus on chromosome 10 as illustrated in Fig. 
2. Ratios obtained from test to reference loci represent 
the integer of CCL3L1 copy number (7). 
Droplet Digital Polymerase Chain Reaction
Development of Digital Polymerase Chain Reaction 
(dPCR) was to improve the conventional PCR by 
partitioning the DNA samples and dividing the PCR 
reaction into smaller and multiple reactions (58). Droplet 
Digital PCR (ddPCR) is the new format of dPCR which 
has been commercialized in 2011 (59). Fig. 3 shows the 
workflow of ddPCR where the droplet generation oil and 
sample are partitioned into thousands of droplets prior 
PCR. Droplet containing targeted DNA is indicated as a 
positive droplet. The fluorescence emitted by positive 
droplets is compared to the reference or negative 
droplets per fluorophore per sample by using the data 
analysis software which provides the concentration of 
target DNA (59).
Figure 3: Schematic showing the workflow of ddPCR. Firstly, 
prepare the sample then followed by partitioning to make ap-
proximately 20,000 droplets containing generation oil. Next, 
run the PCR and read all droplets by measuring the fluores-
cence intensity. The different in fluorescence intensity is cal-
culated in order to determine the copy number.
Several studies had used this method to determine the 
CCL3L1 copy number. Specific probes and primers were 
designed to amplify the exon 1 of CCL3L1 at the 120 
bp sequence. A fluorescent probe and specific primers 
were also prepared for RPP30, the reference gene 
with a known copy number of two for normalization. 
A software (QuantaSoft) was used to quantify the 
CCL3L1 by counting and comparing the signal events 
of positive and negative fluorescence. The positive 
fluorescent correlates to droplets with at least one copy 
of CCL3L1 and the calculation of copy number relies on 
the frequency of negative fluorescence. The final copy 
number values was obtained from the ratio between 
the concentration (copies/uL) of CCL3L1 and RPP30 
(12). Reliability of this method in obtaining a high-level 
precision of copy number measurements relies on the 
multiple reactions of more than 10 000 (approximately 
20 000 reactions in ddPCR). ddPCR is applicable in 
demonstrating a more accurate measurement of CNV 
than qPCR and PRT (60). Besides, the analyses without 
the requirement of the standard curve unlike qPCR and 
Southern blot offers an absolute quantification of copy 
number. It also reduces error rate in PCR as well as lower 
equipment cost needed to perform the procedure (59). 
Single Nucleotide Polymorphism (SNP) Array
SNP array is a technique developed to genotype SNPs by 
using microarray platform (61) and have been extended 
to detect the CNV (62). Affymetrix and Illumina are the 
primary suppliers of SNP array commercially. Both rely 
on the same principle of fragmented single-stranded 
DNA hybridization to arrays even though they use 
different chemistries (63). The principle of this array 
is to capture DNA fragments by using short base-pair 
sequences. In order to infer the copy number, it depends 
on the hybridization intensities of the test DNA sample 
that is co-hybridized to a target sample (63). The SNP 
probe was tagged within or close to the site of the 
CNV and then the total intensity of normalized allelic 
was determined to identify the regions of deletion and 
duplication (64). 
Affymetrix Genome-Wide Human SNP 6.0, has been 
developed with the features of many SNP and CNV 
probes. These probes efficiently capture SNP and 
CNV data simultaneously in a single array with just a 
simple preparation of DNA on the microarray and the 
data is analysed using Genotyping Console Software. 
This array manages to differentiate the frequency of 
CCL3L1 between Tibetans with other populations (65). 
Meanwhile, Illumina HumanHap 550v1 and Illumina 
WG-6 v3 array were used in the determination of 
CCL3L1 and CCL3 mRNA expression (73). Both contain 
specific probe sets designed for CCL3L1 (Illumina probe 
IDs:  1747355, 1773245, and 2218856). The raw data 
of expression must be first normalized to avoid any bias 
in RNA loading and subsequently, linear regression is 
performed to assess the expression data. Later, the effect 
of copy number on expression could be determined (66). 
Detection of CNV by using SNP array has become more 
alluring as there are several new array designs which 
include monomorphic probes to improve the CNV 
analysis (67). Besides, the use of a high probe density 
may increase the sensitivity of SNP array due to more 
detection power (68). Although SNP array can be used 
for copy number detection, the array-based approaches 
like SNP array tend to be inaccurate when involving high 
copy number counts (more than 4 copies) (40). Thus, 
SNP array is not applicable for multi-allelic analysis. 
CONCLUSION
As the conclusion, CCL3L1 copy number has been 
reported in various range among different populations; 
European with 0 to 7 copies, African with 0 to 14 
copies while Asian with 0 to 10 copies. Most of the 
report also associated the copy number with certain 
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diseases particularly HIV. However, limited report 
found on Malaysia which is known as a multi-ethnic 
country that could enhance our knowledge in human 
genetic diversity as well as gene association towards 
ethnic-specific diseases. Moreover, this review gives an 
insight on the appropriate techniques for typing CCL3L1 
copy number. PRT and ddPCR methods are highly 
recommended to detect copy number for multi-allelic 
CNVs as both methods yield good results with high 
accuracy of copy number reported.
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